Trelegy Ellipta® (fluticasone furoate/umeclidinium/vilanterol) – New indication
September 9, 2020 - GlaxoSmithKline announced the FDA approval of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), for the maintenance treatment of asthma in patients aged 18 years and older.
Download PDF
